<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62250">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02136836</url>
  </required_header>
  <id_info>
    <org_study_id>GSCH-STO13-01</org_study_id>
    <secondary_id>Roche</secondary_id>
    <nct_id>NCT02136836</nct_id>
  </id_info>
  <brief_title>Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer</brief_title>
  <acronym>HER2</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the proportion of HER2 overexpression in
      gastric cancer patients group, to evaluate the relation of HER2 overexpression with
      prognosis, and to analyze the proportion of herceptin applied to patients in clinical field.
      Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for
      survival prolongation compared to chemotherapy only.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>The proportion of HER2 overexpression in gastric cancer patients</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer specific survival according to HER2 expression in each stage</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>The practice pattern of Herceptin use in stage IV gastric cancer</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>gastric adenocarcinoma</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        gastric cancer patients in Gangnam Severance Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed gastric adenocarcinoma

          2. Patients were diagnosed during 2006-2013

          3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.

        Exclusion Criteria:

          -  Patients with second primary cancer within 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Yong Cho, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital, Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jae Yong Cho</investigator_full_name>
    <investigator_title>Chief of division of medical oncology, Gangnam Severance Hospital</investigator_title>
  </responsible_party>
  <keyword>Genes, erbB-2</keyword>
  <keyword>Prognosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
